Desfecho das pacientes em tratamento para Câncer de Mama diagnosticadas com Covid 19 no Norte do Tocantins

Abstract

Breast cancer is the malignant neoplasm with the highest mortality among women, and it has a high incidence both in Brazil and worldwide. Its causes are multifactorial and as this pathology presents several treatments, we should take into account some factors for its application. Since the emergence of the pandemic caused by the SARS-CoV-2, there are doubts about the evolution of COVID-19 in oncologic patients as well as its impact on the different stages of treatment. Therefore, as we face two pathologies of high incidence and great impact on mortality, studies correlating the two diseases are necessary. The objective of this study was to evaluate the outcome of patients diagnosed with COVID-19, who started treatment for breast cancer between 03/18/20 to 07/31/21, in Northern Tocantins. The studied group was composed by patients who were diagnosed with COVID-19 and also were undergoing treatment for breast cancer, regardless of the treatment phase. This is a retrospective and descriptive study that took place between March 2020 and July 2021. The patients were questioned about the clinical course after being infected with SARS- CoV-2 and we evaluated the outcomes in this group of patients and correlated them with the stage of oncological treatment. We observed that patients with COVID-19 in hormone therapy did not require hospitalization, while 50% of patients undergoing chemotherapy required hospitalization, however, none of the hospitalized women needed to be transferred to an ICU. Therefore we can conclude that the stage of cancer treatment interfered with morbidity, but did not alter the mortality of these women.